Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NGM438 Monotherapy and in Combination With Pembrolizumab in Solid Tumors
NCT05311618Phase 1Active, not recruiting
- Sponsor
- NGM Biopharmaceuticals
- Start
- May 2022
- Primary completion
- Apr 2025
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of NGM438 in pancreatic cancer (PC), breast cancer, gastric cancer (GC) and 13 more, sponsored by NGM Biopharmaceuticals. Primary endpoints: Number of Patients with Dose-limiting Toxicities at 21 days, Number of Patients with Adverse Events at 24 months and 4 more. Started May 2022; status: active, not recruiting.
02
Drugs
NGM438
03
Conditions
pancreatic cancer (PC)breast cancergastric cancer (GC)non-small cell lung cancer (NSCLC)Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT05311618.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05311618.